Expert Review of Respiratory Medicine,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 11
Published: Nov. 3, 2024
Introduction
In
the
era
of
precision
medicine,
liquid
biopsy
rapidly
emerges
as
an
integrative
diagnostic
tool
to
successfully
stratify
solid
tumor
patients
in
accordance
with
molecular
fingerprinting.
As
matter
fact,
a
plethora
analytes
may
be
isolated
from
biosources
supporting
potential
application
several
clinical
scenarios.
Despite
this
promising
role,
is
drastically
affected
by
low
abundance
biological
matrix
requiring
highly
sensitive
technologies,
trained
personnel,
and
optimized
procedures
administrate
revolutionary
practice.
npj Breast Cancer,
Journal Year:
2024,
Volume and Issue:
10(1)
Published: June 19, 2024
Abstract
Circulating
free
tumor
DNA
(ctDNA)
analysis
is
gaining
popularity
in
precision
oncology,
particularly
metastatic
breast
cancer,
as
it
provides
non-invasive,
real-time
information
to
complement
tissue
biopsies,
allowing
for
tailored
treatment
strategies
and
improved
patient
selection
clinical
trials.
Its
use
early
cancer
has
been
limited
so
far,
due
the
relatively
low
sensitivity
of
available
techniques
a
setting
characterized
by
lower
levels
ctDNA
shedding.
However,
advances
sequencing
bioinformatics,
well
methylome
profiles,
have
led
an
increasing
interest
application
from
screening
curative
evaluation
minimal
residual
disease
(MRD)
detection.
With
multiple
prospective
trials
this
setting,
may
become
useful
practice.
This
article
reviews
data
regarding
analytical
validity
currently
tests
detection
potential
cancer.
Science Advances,
Journal Year:
2024,
Volume and Issue:
10(15)
Published: April 10, 2024
We
report
an
approach
for
cancer
phenotyping
based
on
targeted
sequencing
of
cell-free
DNA
(cfDNA)
small
cell
lung
(SCLC).
In
SCLC,
differential
activation
transcription
factors
(TFs),
such
as
ASCL1,
NEUROD1,
POU2F3,
and
REST
defines
molecular
subtypes.
designed
a
capture
panel
that
identifies
chromatin
organization
signatures
at
1535
TF
binding
sites
13,240
gene
start
detects
exonic
mutations
in
842
genes.
Sequencing
cfDNA
from
SCLC
patient-derived
xenograft
models
captured
activity
expression
revealed
individual
highly
informative
loci.
Prediction
ASCL1
NEUROD1
using
loci
achieved
areas
under
the
receiver
operating
characteristic
curve
(AUCs)
0.84
to
0.88
patients
with
SCLC.
As
non-SCLC
(NSCLC)
often
transforms
following
therapy,
we
applied
our
framework
distinguish
NSCLC
AUC
0.99.
Our
shows
promising
utility
subtyping
transformation
monitoring,
potential
applicability
diverse
tumor
types.
The Journal of Liquid Biopsy,
Journal Year:
2025,
Volume and Issue:
unknown, P. 100293 - 100293
Published: March 1, 2025
Liquid
biopsy
(LB)
has
emerged
as
a
transformative
tool
in
oncology,
providing
minimally
invasive
approach
for
tumor
detection,
molecular
characterization,
and
real-time
treatment
monitoring.
By
analyzing
circulating
DNA
(ctDNA),
cells
(CTCs),
extracellular
vesicles
(EVs),
microRNA
(miRNA),
LB
enables
comprehensive
profiling
without
the
need
traditional
tissue
biopsies.
Over
past
decade,
research
this
field
expanded
exponentially,
leading
to
integration
of
into
clinical
practice
specific
cancer
types,
including
lung
breast
cancer.
In
2024,
Journal
Biopsy
(JLB)
published
innovative
studies
exploring
latest
advancements
technologies,
biomarkers,
their
applications
minimal
residual
disease
(MRD)
monitoring,
therapy
response
assessment.
This
review
synthesizes
recent
findings
on
role
monitoring
across
different
with
particular
focus
newly
context
within
translational
research.
Additionally,
it
highlights
emerging
techniques
such
fragmentomics,
artificial
intelligence,
multiomics,
paving
way
more
precise,
personalized
decisions.
Despite
these
advancements,
challenges
remain
standardizing
methodologies,
optimizing
validation,
integrating
routine
oncological
workflows.
mini-review
evolving
landscape
its
potential
revolutionize
diagnosis,
therapeutic
decision-making,
ushering
new
era
precision
oncology.
AI in Precision Oncology,
Journal Year:
2024,
Volume and Issue:
1(2), P. 91 - 105
Published: April 1, 2024
Introduction:
Early
cancer
detection
can
lead
to
improved
outcomes
and
a
shift
toward
prevention
model.
This
review
explores
the
role
of
artificial
intelligence
(AI)
in
early
detection,
focusing
on
its
application
various
clinical
settings.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(12), P. 2280 - 2280
Published: June 20, 2024
CtDNA
is
emerging
as
a
non-invasive
clinical
detection
method
for
several
cancers,
including
genitourinary
(GU)
cancers
such
prostate
cancer,
bladder
and
renal
cell
carcinoma
(RCC).
assays
have
shown
promise
in
early
of
GU
providing
prognostic
information,
assessing
real-time
treatment
response,
detecting
residual
disease
relapse.
The
ease
obtaining
“liquid
biopsy”
from
blood
or
urine
enhances
its
potential
to
be
used
biomarker.
Interrogating
these
biopsies”
ctDNA
can
then
detect
common
cancer
mutations,
novel
genomic
alterations,
epigenetic
modifications.
has
undergone
investigation
numerous
trials,
which
could
address
needs
instance,
earlier
RCC,
therapeutic
response
prediction
castration-resistant
monitoring
recurrence
cancers.
utilization
liquid
biopsy
analysis
provides
promising
advancing
precision
medicine
within
the
field
